• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·CBSC
Share

Cardiac Biotech Solutions Inc. Stocks

$ 0.03Last Updated 29.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 4.96M

$ 0.03
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating globally through its international subsidiaries, Cardiac Biotech Solutions Inc. delivers advanced products and services for non-invasive, mobile cardiac monitoring. The company's portfolio includes FDA and CE-approved EKG devices, sophisticated cloud-based data acquisition software, and intuitive smartphone applications compatible with both iOS and Android platforms. These solutions are designed to boost patient engagement for individuals prone to irregular heart rhythms, simultaneously providing medical professionals with highly accurate diagnostic insights. Furthermore, its wholly owned U.S. subsidiary, My-Cardia (USA), Inc., focuses on creating wearable ECG recording devices that patients can utilize in an ambulatory setting for periods extending up to 30 days.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 00:22

"These scars have cost us dearly": "AI Nostradamus" promised not to borrow money anymore

31.07.2026 22:26

The Kazakh Market: CPC as a Risk Factor, the Summer Slowdown, and Weakening Support for the Tenge

31.07.2026 21:55

Roblox shares plummeted 30%. Analysts have begun advising investors to sell them

31.07.2026 21:48

Worst reaction to an earnings report in 13 years: Apple risks losing $460 billion in market value in a single day

31.07.2026 21:35

Three Fed officials said interest rates need to be raised to combat inflation

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026